Cited 37 times in
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.